Not provided
Not provided
Not provided
Not provided
investigator choice
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Known to reduce analgesics and length of hospitalization in conventional surgery, laparoscopy is characterized by frequent post-operative pain and can decrease the patient's quality of immediate postoperative life and sometimes the results of decision ambulatory care.
In order to reduce these postoperative pain, various methods have been evaluated in numerous studies to determine their analgesic role.
As part of abdominal surgery, local anesthetics (Naropin (Ropivacaine)) are generally administered in the end of surgery to reduce postoperative pain and promote recovery of the patient. In addition, it is also possible to instill the anesthetic directly into the abdominal cavity reducing pain transmitted by nociceptor viscera.
In recent years, new methods have been proposed such as lung recruitment maneuvers and the instillation of saline solution to reduce postoperative pain.
However, no recommendation is on the use of intraperitoneal saline under the management of postoperative pain after laparoscopic cholecystectomy in ambulatory care.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ropivacaine | Active Comparator | Ropivacaine 7.5 mg/mL administration |
|
| Sodium chloride | Placebo Comparator | NaCl 0.9% administration |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sodium chloride administration | Drug | Sodium chloride administration |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Pain measured by visual analog scale (VAS) | between first postoperative day and 6th postoperative day |
| Measure | Description | Time Frame |
|---|---|---|
| global pain measured by BPI (Brief Pain Inventory) scale | 30th postoperative day | |
| analgesics use | 30th postoperative day | |
| global morbidity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-Marc REGIMBEAU, MD, PhD | CHU Amiens | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Amiens | Amiens | 80054 | France | |||
| CH Beauvais |
Not provided
Not provided
Not provided
Not provided
Not provided
| Ropivacaine administration |
| Drug |
Ropivacaine administration |
|
| 30th postoperative day |
| specific complications for each treatment | 30th postoperative day |
| Beauvais |
| 60000 |
| France |
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided